Development of COVID-19 vaccines utilizing gene therapy technology
- PMID: 33772572
- PMCID: PMC8083619
- DOI: 10.1093/intimm/dxab013
Development of COVID-19 vaccines utilizing gene therapy technology
Abstract
There is currently an outbreak of respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) is caused by infection with SARS-CoV-2. Individuals with COVID-19 have symptoms that are usually asymptomatic or mild in most initial cases. However, in some cases, moderate and severe symptoms have been observed with pneumonia. Many companies are developing COVID-19 vaccine candidates using different technologies that are classified into four groups (intact target viruses, proteins, viral vectors and nucleic acids). For rapid development, RNA vaccines and adenovirus vector vaccines have been urgently approved, and their injection has already started across the world. These types of vaccine technologies have been developed over more than 20 years using translational research for use against cancer or diseases caused by genetic disorders but the COVID-19 vaccines are the first licensed drugs to prevent infectious diseases using RNA vaccine technology. Although these vaccines are highly effective in preventing COVID-19 for a short period, safety and efficiency evaluations should be continuously monitored over a long time period. As the time of writing, more than 10 projects are now in phase 3 to evaluate the prevention of infection in double-blind studies. Hopefully, several projects may be approved to ensure high-efficiency and safe vaccines.
Keywords: SARS-CoV-2; gene therapy; virus vector.
© The Japanese Society for Immunology. 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1. Arch Razi Inst. 2021. PMID: 33818952 Free PMC article.
-
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24. Lancet Infect Dis. 2021. PMID: 33773111 Free PMC article. Clinical Trial.
-
Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.Rev Med Virol. 2021 May;31(3):e2183. doi: 10.1002/rmv.2183. Epub 2020 Oct 15. Rev Med Virol. 2021. PMID: 33594794 Free PMC article. Review.
-
SARS-CoV-2 vaccine candidates in rapid development.Hum Vaccin Immunother. 2021 Mar 4;17(3):644-653. doi: 10.1080/21645515.2020.1804777. Epub 2020 Oct 29. Hum Vaccin Immunother. 2021. PMID: 33121319 Free PMC article. Review.
-
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.Front Immunol. 2021 Jun 30;12:658519. doi: 10.3389/fimmu.2021.658519. eCollection 2021. Front Immunol. 2021. PMID: 34276652 Free PMC article. Review.
Cited by 2 articles
-
PolyPurine Reverse Hoogsteen Hairpins Work as RNA Species for Gene Silencing.Int J Mol Sci. 2021 Sep 16;22(18):10025. doi: 10.3390/ijms221810025. Int J Mol Sci. 2021. PMID: 34576188 Free PMC article.
-
Therapeutic vaccine for chronic diseases after the COVID-19 Era.Hypertens Res. 2021 Sep;44(9):1047-1053. doi: 10.1038/s41440-021-00677-3. Epub 2021 Jun 8. Hypertens Res. 2021. PMID: 34099884 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
